
    
      Eligible patients will receive one dose of cemiplimab-rwlc, via infusion, one week prior to
      standard of care craniotomy and tumor resection (subtotal or total). On the day of surgery,
      patients will receive one dose of veledimex before the resection procedure. Ad-RTS-hIL-12
      will be administered by free-hand injection. Patients will continue on oral veledimex for 14
      days. Following veledimex, patients will receive cemiplimab-rwlc via infusion every three
      weeks.

      The study is divided into three periods: the screening period, the treatment period and the
      follow-up period.
    
  